Approach to Cognitive Impairment in Parkinson's Disease

Area of Science:

• Neurology
• Neuroscience
• Cognitive Science

Background:

• Cognitive dysfunction is prevalent in Parkinson's disease (PD), significantly impacting patient outcomes.
• Pathological changes in basal forebrain cholinergic and prefrontal dopaminergic systems are primary drivers.
• Hallmark cognitive impairments include executive dysfunction, attention deficits, and visuospatial difficulties, progressing to memory issues.

Purpose of the Study:

• To review the current understanding of cognitive dysfunction in Parkinson's disease.
• To discuss the progression from early subtle symptoms to mild cognitive impairment (MCI) and dementia.
• To explore current and potential therapeutic strategies for cognitive impairment in PD.

Main Methods:

• Literature review of studies on cognitive impairment in Parkinson's disease.
• Analysis of the neuropathological underpinnings of cognitive deficits.
• Evaluation of pharmacological and non-pharmacological interventions.

Main Results:

• Mild cognitive impairment (MCI) can be present at diagnosis and progresses to dementia in most PD patients.
• Dopaminergic medications and deep brain stimulation may cause cognitive side effects.
• Acetylcholinesterase inhibitors and memantine offer modest, temporary symptomatic relief for dementia, with no proven treatments for MCI.

Conclusions:

• There are no proven disease-modifying treatments for cognitive impairment in Parkinson's disease.
• The roles of physical exercise, cognitive training, and neuromodulation are under investigation.
• Multidisciplinary approaches, including managing comorbidities and providing support, are crucial for improving quality of life.